Activin receptor type-1B (EC 2.7.11.30) (Activin receptor type IB) (ACTR-IB) (Activin receptor-like kinase 4) (ALK-4) (Serine/threonine-protein kinase receptor R2) (SKR2) | P36896 | 2.3e-5 | 4.0e-1 | Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol. 2009 May;20(5):1053-67. doi: 10.1681/ASN.2008070798. Epub 2009 Apr 23. | ENOG410XQT0 | 18 / 0 / 18 |
Activin receptor type-1B (EC 2.7.11.30) (Activin receptor type IB) (ACTR-IB) (Activin receptor-like kinase 4) (ALK-4) (Serine/threonine-protein kinase receptor R2) (SKR2) | P36896 | 2.3e-5 | 4.0e-1 | Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol. 2009 May;20(5):1053-67. doi: 10.1681/ASN.2008070798. Epub 2009 Apr 23. | ENOG410XQT0 | 18 / 0 / 18 |
Activin receptor type-1B (EC 2.7.11.30) (Activin receptor type IB) (ACTR-IB) (Activin receptor-like kinase 4) (ALK-4) (Serine/threonine-protein kinase receptor R2) (SKR2) | P36896 | 0.0e+0 | 1.1e-14 | Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol. 2009 May;20(5):1053-67. doi: 10.1681/ASN.2008070798. Epub 2009 Apr 23. | ENOG410XQT0 | 18 / 0 / 18 |
Activin receptor type-1B (EC 2.7.11.30) (Activin receptor type IB) (ACTR-IB) (Activin receptor-like kinase 4) (ALK-4) (Serine/threonine-protein kinase receptor R2) (SKR2) | P36896 | 0.0e+0 | 3.7e-7 | Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol. 2009 May;20(5):1053-67. doi: 10.1681/ASN.2008070798. Epub 2009 Apr 23. | ENOG410XQT0 | 18 / 0 / 18 |
Activin receptor type-1B (EC 2.7.11.30) (Activin receptor type IB) (ACTR-IB) (Activin receptor-like kinase 4) (ALK-4) (Serine/threonine-protein kinase receptor R2) (SKR2) | P36896 | 0.0e+0 | 4.9e-1 | Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics. 2009 Nov 25;10:556. doi: 10.1186/1471-2164-10-556. | ENOG410XQT0 | 18 / 0 / 18 |
Activin receptor type-1B (EC 2.7.11.30) (Activin receptor type IB) (ACTR-IB) (Activin receptor-like kinase 4) (ALK-4) (Serine/threonine-protein kinase receptor R2) (SKR2) | P36896 | 0.0e+0 | 3.7e-1 | RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer. 2012 Jan 17;12:22. doi: 10.1186/1471-2407-12-22. | ENOG410XQT0 | 18 / 0 / 18 |
Activin receptor type-1B (EC 2.7.11.30) (Activin receptor type IB) (ACTR-IB) (Activin receptor-like kinase 4) (ALK-4) (Serine/threonine-protein kinase receptor R2) (SKR2) | P36896 | 0.0e+0 | 3.3e-1 | RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer. 2012 Jan 17;12:22. doi: 10.1186/1471-2407-12-22. | ENOG410XQT0 | 18 / 0 / 18 |
Activin receptor type-1B (EC 2.7.11.30) (Activin receptor type IB) (ACTR-IB) (Activin receptor-like kinase 4) (ALK-4) (Serine/threonine-protein kinase receptor R2) (SKR2) | P36896 | 0.0e+0 | 4.4e-1 | First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications. Biol Cell. 2013 Jul;105(7):289-303. doi: 10.1111/boc.201200086. Epub 2013 May 4. | ENOG410XQT0 | 18 / 0 / 18 |
Activin receptor type-1B (EC 2.7.11.30) (Activin receptor type IB) (ACTR-IB) (Activin receptor-like kinase 4) (ALK-4) (Serine/threonine-protein kinase receptor R2) (SKR2) | P36896 | 0.0e+0 | 4.4e-1 | First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications. Biol Cell. 2013 Jul;105(7):289-303. doi: 10.1111/boc.201200086. Epub 2013 May 4. | ENOG410XQT0 | 18 / 0 / 18 |
Activin receptor type-1B (EC 2.7.11.30) (Activin receptor type IB) (ACTR-IB) (Activin receptor-like kinase 4) (ALK-4) (Serine/threonine-protein kinase receptor R2) (SKR2) | P36896 | 1.9e-15 | 4.8e-1 | First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications. Biol Cell. 2013 Jul;105(7):289-303. doi: 10.1111/boc.201200086. Epub 2013 May 4. | ENOG410XQT0 | 18 / 0 / 18 |